Skip to content

ACRO BIOMEDICAL CO., LTD.: 10-Q filed 2026-05-05

What ACRO BIOMEDICAL CO., LTD. reported in its quarterly report filed 2026-05-05 (fiscal Q1 2026): 21 published measures, 46 facts as tagged in accession 0001640334-26-000824.

This filing

Form
10-Q (quarterly report)
Filed
2026-05-05
Fiscal period
fiscal Q1 2026
Accession
0001640334-26-000824 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ACRO BIOMEDICAL CO., LTD. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2026-03-313,873USD
At 2025-12-3114,098USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2026-03-31-427,235USD
At 2025-12-31-386,964USD
At 2025-03-31-303,906USD
At 2024-12-31-294,972USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2026-01-01 to 2026-03-31-43,774USD90
2025-01-01 to 2025-03-31-10,301USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2026-01-01 to 2026-03-31-49,821USD90
2025-01-01 to 2025-03-31-22,531USD90

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2026-01-01 to 2026-03-310USD90
2025-01-01 to 2025-03-310USD90

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2026-01-01 to 2026-03-3149,596USD90
2025-01-01 to 2025-03-3122,306USD90

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2026-03-31-32,802,715USD
At 2025-12-31-32,758,941USD

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2026-01-01 to 2026-03-3160,042,000shares90
2025-01-01 to 2025-03-3160,042,000shares90

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2026-01-01 to 2026-03-310USD/shares90
2025-01-01 to 2025-03-310USD/shares90

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2026-01-01 to 2026-03-31-60,271USD90
2025-01-01 to 2025-03-31-8,934USD90

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2026-03-313,873USD
At 2025-12-3114,098USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2026-03-31431,108USD
At 2025-12-31401,062USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2026-01-01 to 2026-03-3160,271USD90
2025-01-01 to 2025-03-318,934USD90

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2026-01-01 to 2026-03-3160,271USD90
2025-01-01 to 2025-03-318,934USD90

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2026-03-3160,042,000shares
At 2025-12-3160,042,000shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2026-03-313,873USD
At 2025-12-314,098USD
At 2025-03-31251USD
At 2024-12-31476USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2026-03-3132,315,438USD
At 2025-12-3132,311,935USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2026-01-01 to 2026-03-31-43,774USD90
2025-01-01 to 2025-03-31-10,301USD90

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2026-01-01 to 2026-03-3116,497USD90
2025-01-01 to 2025-03-31-1,367USD90

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2026-01-01 to 2026-03-310USD90
2025-01-01 to 2025-03-310USD90

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2026-01-01 to 2026-03-310USD90
2025-01-01 to 2025-03-310USD90

Inspect the source

Entity
ACRO BIOMEDICAL CO., LTD. / CIK 0001622996
Captured
2026-09-19T11:19:47.057Z
SEC response SHA-256
b3abbbd950a9b9c0ba03d5604cc52c43ddb41d59ea263147bca632d90b36b6c9

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001622996.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))